Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $44.67.

TEVA has been the topic of several analyst reports. Oppenheimer began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price target on the stock. Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company. Weiss Ratings downgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 8th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 374,959 shares of company stock worth $14,644,285 in the last 90 days. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. QRG Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 17.0% in the second quarter. QRG Capital Management Inc. now owns 89,078 shares of the company’s stock worth $3,018,000 after acquiring an additional 12,925 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Teva Pharmaceutical Industries by 7.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after purchasing an additional 483 shares during the last quarter. Bullseye Investment Management LLC acquired a new position in Teva Pharmaceutical Industries during the second quarter worth approximately $68,000. Sequoia Financial Advisors LLC raised its stake in Teva Pharmaceutical Industries by 12.5% during the second quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company’s stock worth $6,469,000 after purchasing an additional 21,240 shares during the period. Finally, National Pension Service raised its stake in Teva Pharmaceutical Industries by 4.9% during the second quarter. National Pension Service now owns 2,406,013 shares of the company’s stock worth $81,516,000 after purchasing an additional 112,357 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $39.05 on Wednesday. Teva Pharmaceutical Industries has a fifty-two week low of $18.83 and a fifty-two week high of $40.79. The stock has a market cap of $45.50 billion, a price-to-earnings ratio of 65.08, a price-to-earnings-growth ratio of 3.78 and a beta of 0.89. The business has a fifty day moving average of $37.35 and a 200-day moving average of $34.29. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, analysts predict that Teva Pharmaceutical Industries will post 1.93 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.